22 1.2.3.1 La morphine, p.24 ,
La constipation sous opioïdes, 2008. ,
En ligne] [Citation : 22 11 2013 ,
[En ligne] [Citation : 23 11 2013 ,
Orally Administered Paracetamol Does Not Act Locally in the Rat Formalin Test, Anesthesiology, vol.99, issue.4, 2003. ,
DOI : 10.1097/00000542-200310000-00034
Paracétamol : toxicité hépatique aux doses thérapeutiques et populations à risque. Revue Médicale Suisse, p.129, 2007. ,
Acute versus chronic alcohol consumption in acetaminophen-induced hepatotoxicity. s.l. : Hepatology, pp.876-82, 2002. ,
Les anti-inflammatoires non-steroidiens ,
Traitement par néfopam des douleurs abdominales de l'adulte en médecine ambulatoire d'urgence par les praticiens de SOS Médecins 54 : Enquête de pratiques sur l'utilisation des voies injectable et sub-linguale, p.114, 2009. ,
Commission de la transparence néfopam, HAS. [En ,
Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives, Journal of Gastroenterology, vol.70, issue.2, pp.92-215, 2013. ,
DOI : 10.1002/ana.22446
Les médicaments des accès douloureux paroxystiques du cancer. HAS santé. [En ligne] Septembre 2011. [Citation : 22 Décembre 2013 ,
Breakyl®. www.vidal.fr. [En ligne] 18 04 2013. [Citation : 23 01, 2014. ,
Misselijkeid en braken. pallialine.be. [En ligne] [Citation : 09 11 2013 ,
The Role of Ketamine in Preventing Fentanyl-Induced Hyperalgesia and Subsequent Acute Morphine Tolerance, s.l. : Anesthesia and analgesia, 2002. ,
DOI : 10.1097/00000539-200205000-00040
Clinical Pharmacology Review of RELISTOR. s.l. : FDA, pp.21-964, 2007. ,
Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation. s.l. : Drug Dev Ind Pharm, 2013. ,
European Public Assessment Report of RELISTOR. [En ligne] 05 08 [Citation : 12 01 2014, 2009. ,
Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness, New England Journal of Medicine, vol.358, issue.22, 2008. ,
DOI : 10.1056/NEJMoa0707377
Laxatives or methylnaltrexone for the management of constipation in palliative care patients. s.l. : The Cochrane database of systematic reviews, 2011. ,
Comission de transparence. HAS-Santé ,
The Prevalence, Severity, and Impact of Opioid-Induced Bowel Dysfunction: Results of a US and European Patient Survey (PROBE 1), Pain Medicine, vol.61, issue.1, 2009. ,
DOI : 10.12968/bjon.2006.15.4.20542
Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain, Neurogastroenterology & Motility, vol.101, issue.4, pp.4-424, 2010. ,
DOI : 10.7326/0003-4819-101-3-331
The relationship between opioid use and laxative use in terminally ill cancer patients. Palliative medicine, pp.9-375, 1998. ,
A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation, European Journal of Pain, vol.22, issue.1, pp.56-64, 2008. ,
DOI : 10.1177/104990910502200511
Analgesic Efficacy and Safety of Oxycodone in Combination With Naloxone as Prolonged Release Tablets in Patients With Moderate to Severe Chronic Pain, The Journal of Pain, vol.9, issue.12 ,
DOI : 10.1016/j.jpain.2008.06.014
Code postal ,
Stnuégie de prise en charge des effets indésirables liés aux traitements antalgiques par morphiniques ,
utilisation d'un nouveau traitement contre la constipation au service d'oncologie du CHR de MelZ ,